Prilium 150 mg

Country: New Zealand

Language: English

Source: Ministry for Primary Industries

Active ingredient:

imidapril hcl

Available from:

Ethical Agents Veterinary Marketing Limited

INN (International Name):

imidapril hcl

Composition:

imidapril hcl 170 g/kg

Therapeutic area:

Cardiovascular agent

Authorization status:

ACVM Registered

Authorization date:

2005-07-22

Summary of Product characteristics

  PRILIUM
®
 150mg
Imidapril HCL Oral powder for reconstitution 170 g/kg as freeze dried
powder or 5 g/L reconstituted solution
Indications
In dogs: treatment of heart failure of stages II, III and IV according
to
the NYHA classification, caused by mitral regurgitation or by dilated
cardiomyopathy. The product may be combined, if necessary, with
diuretics such as furosemide and/or with digoxin.
Imidapril is a new angiotensin-converting enzyme (ACE) inhibitor.
Pharmacodynamic properties:
Imidapril is a pro-drug, which is hydrolysed in vivo to form an active
metabolite, imidaprilat. Imidaprilat inhibits the
angiotensin-converting
enzyme (ACE). This enzyme catalyses the conversion of angiotensin
I to angiotensin II in the blood plasma and tissues and inhibits the
breakdown of bradykinin. As angiotensin II has a potent
vasoconstrictive
action, while bradykinin is a vasodilator, the reduced formation of
angiotensin II and the inhibition of bradykinin breakdown lead to
vasodilation. In addition, plasma angiotensin II induces the release
of aldosterone in the renin-angiotensin system. Imidaprilat therefore
reduces the secretion of aldosterone. This leads to an increase in the
serum potassium concentration and a decrease in the serum sodium
concentration.
So, imidapril reduces heart preload and postload, and decreases blood
pressure without any compensatory increase in the heart rate arising.
Pharmacokinetic properties:
Following oral administration in the dog, imidapril is rapidly
absorbed
by the gastrointestinal tract and reaches its maximum plasma
concentration within less than one hour. The half-life of imidapril is
about 2 hours.
Imidapril is mainly hydrolysed in the liver and kidney to its active
Veterinary Pharmaceuticals
70204 LURE Cedex (France)
metabolite, imidaprilat. Maximum plasma concentrations of imidaprilat
are reached within about 5 hours and decline with a half-life of more
than 10 hours.
The bioavailability of imidapril and imidaprilat is decreased by the
joint
administration of food.
The prot